CHLZT protects against NAFLD by activating AMPKα, and also by inhibiting ACC activity, down-regulating SREBP2 and HMGR, and up-regulating PPAR-γ. The gene discussed is HMGA1; the disease is metabolic dysfunction-associated steatotic liver disease.